Johnson & Johnson Professional Inc.
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Johnson & Johnson Professional Inc.
Could Cash-Strapped Idorsia Really Go It Alone With Newly Approved Tryvio?
CEO Jean-Paul Clozel insists Idorsia could launch the first-in-class hypertension drug alone, but analysts think a deal will be done soon – with the only question being for how much.
Strong RSV Vaccine Results Gives GSK An Edge Over Rival Pfizer
GSK looks to have established an efficacy edge over its rivals in developing a vaccine against the respiratory syncytial virus, but analysts expect early 2023 approvals to spark a closely fought contest.
COVID-19 Accounts For Most Of 2020’s Pharma Pipeline Growth
The impact of the coronavirus pandemic on the size of the pharma R&D pipeline in 2020 could be felt in a number of ways.
CRF Leaders Take A Long Look At Medtech
Cardiovascular Research Foundation leaders Jack Lewin, Juan Granada, and Ori Ben-Yehuda talk to IN VIVO about the state of medtech innovation and health care in the US.
Company Information
- Industry
- Medical Devices
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice